The FCF Life Sciences Venture Capital Monitor – Europe is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies, displaying Venture capital financing trends in the European Life Sciences industry.
As of the end of September 2021 we identify the following current VC trends in Europe:
- In 2021, overall Life Sciences funding has reached EUR 9,955m so far
- Top 5 Deals exceed EUR 190m each, largest transaction amounted to EUR 497m in CMR Surgical Ltd. (United Kingdom)
- BlackRock (USA) still dominates the Top 5 Investors (by deal volume), followed by Fidelity Management & Research (USA) and Novo Holdings (Denmark)
- The Biotechnology sector received 43% of the total investment volume (-7% points compared to the previous month)
- Oncology dominates as the top indication
Capital Markets Research
We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:
Venture Capital
Licensing
Life Sciences Venture Capital Monitor – Europe
Monthly Venture capital activities in the European Life Sciences sector
Biotech Venture Capital Monitor – USAMonthly Venture capital activities in the US Life Sciences sector
Life Sciences Venture Capital ReportRecent Venture capital trends in the European Life Sciences sector
Other Research
Life Sciences IPO ReportRecent IPO trends in the Life Sciences sector
Biotech Public Equity MonitorRecent valuations of listed European Life Sciences companies
MedTech & Diagnostics Public Equity MonitorRecent valuations of listed MedTech companies
Life Sciences SPAC MonitorPerformance overview of merged Life Sciences SPACs
NEWS
Psychedelics attract more VC investments
Investment into US and European psychedelics companies have been continuously increasing over the past years as mental health gains in importance. Whereas only 12 venture capital transactions were conducted in 2016, the number of transactions
Positive performance of venture capital funding for European life sciences companies
In the third quarter of 2021, European life sciences companies raised a total of EUR 2.2bn in venture capital funding. Although the performance is almost the same as in the same quarter last year, the
Cumulated US Biotech Venture Capital Funding exceeds total volume of 2020 already in the third quarter of 2021
With a volume of roughly USD 24bn, US biotech companies have already raised more venture capital in the first three quarters of 2021 than in the whole year 2020 (USD 22.4bn). Compared to the first
Negative life sciences sentiments recorded in September 2021
In the course of the monthly published FCF Life Sciences Venture Capital Monitor – Europe, the FCF Life Sciences team analyses the current sentiments in European life sciences venture capital funding per subsector. In September
FCF Biotech Venture Capital Monitor – USA 09/2021 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 09/2021”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
